American Society of Clinical Oncology
ASCO
Companies share robust oncology data at annual ASCO meeting.
During the full presentation of the abstract on Friday, Janssen will show that treatment with Erleada significantly improved rPFS with a reduction in the risk of death by 52%. Additionally, in overall survival, the TITAN data showed Erleada and ADT significantly improved OS with a 33% reduction in risk of death.
With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
The American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) is being held in San Francisco from February 14-16. Ahead of the conference, several companies have announced presentations. Here’s a look at just a few.
There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
Basel, Switzerland-based Novartis announced that between the ASCO meeting and the 23rd Annual Congress of the European Hematology Association (EHA) meeting being held June 14 to 17 in Stockholm, Sweden, it will be presenting 84 abstracts.
Wednesday was the big day for pharma and biotech companies to unveil abstracts ahead of the annual American Society of Oncology meeting in Chicago next month. Some companies have unveiled positive results that are making investors happy, while others… not so much.
Loxo Oncology shares climbed 19 percent after data for its cancer drug LOXO-292 was released.
PRESS RELEASES